Современные представления о серологических опухолеассоциированных маркерах и их месте в онкологии

Обзор посвящен современным представлениям о серологических опухолеассоциированных маркерах (ОМ) и их месте в онкологии: использовании для дифференциальной диагностики, в прогнозе течения опухолевого процесса, мониторинге и для доклинического выявления рецидивов болезни, а также в скрининге, направленном на раннее выявление злокачественных новообразований. Описаны биохимические характеристики и функции наиболее информативных ОМ (СА125, ПСА и др). В настоящее время с целью повышения диагностической точности в лабораторной практике начинают применяться диагностические индексы, полученные путем многопараметрического анализа in vitro (in vitro diagnostic multivariate index assay, IVDMIA), 
и алгоритмы с использованием нескольких серологических маркеров. Также в обзоре описаны некоторые новые перспективные серологические ОМ.

1. European Group on Tumor markers (EGTM): Consensus recommendations. Anticancer Res 1999;19(4A):2789–819.

2. Сергеева Н.С., Маршутина Н.В. Серологические опухолеассоциированные маркеры. В кн.: Онкология. Национальное руководство (под ред. В.И. Чиссова, М.И. Давыдова. .: ГЭОТАР-медиа, 2008. С. 41–73.

3. Абелев Г.И. Эмбриональные антигены в опухолях. Анализ в системе альфа-фетопротеина. Опухолевый рост как проблема биологического развития. М., 1979. С.148–173.

4. Gold P., Freedman S.O. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965;121:439–62.

5. Эпоним. Белок Бенс-Джонса. Клиническая нефрология 2010;6:77.

6. Говорун В.М., Иванов В.Т. Протеомика и пептидомика в фундаментальных и прикладных медицинских исследованиях. Биоорг химия 2011;37(2):199–215.

7. Duffi M.J. How to Validate a New Cancer Biomarker: From Discovery to Clinical Application. Tumor Biology 2014;35(1):5.

8. Faten-Moghadam A., Stieber P. Sensible use of tumor markers. J. Hartmann (ed). Basel: Springer-Verlag, 1993. 70S.

9. Руководство по онкологии. Под ред. В.И. Чиссова, С.Л. Дарьяловой. М.: Медицинское информационное агентство, 2008. C. 835.

10. Бережная Н.М., Чехун В.Ф. Иммунология злокачественного роста. К.: Наукова думка, 2005. C. 791.

11. Телетаева Г.М. Цитокины и противоопухолевый иммунитет. Практическая онкология 2007;8(4):211–8.

12. Schneider J., Philipp M., Velcovsky H.G. et al. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-ragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Anticancer Res 2003;23:885–93.

13. Bafna S., Kaur S., Batra S.K. Membranebound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene 2010;29(20): 2893–904.

14. O'Brien T.J., Beard J.B., Underwood L.J. et al. The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumor Biol 2002;23(3):154–69.

15. Bast R.C. Jr, Feeney M., Lazarus H. et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68(5):1331–7.

16. Hardardottir H., Parmley T.H., Quirk J.G. et al. Distribution of CA 125 in embryonic tissues and adult derivatives of the fetal periderm. Am J Obstet Gynecol 1990;163(6 Pt 1):1925– 31.

17. Blalock T.D., Spurr-Michaud S.J., Tisdale A.S. et al. Functions of MUC16 in corneal epithelial cells. Invest Ophthalmol Vis Sci 2007;48(10):4509–18.

18. Gipson I.K., Blalock T., Tisdale A. et al. MUC16 is lost from the uterodome (pinopode) surface of the receptive human endometrium: in vitro evidence that MUC16 is a barrier to trophoblast adherence. Biol Reprod 2008;78(1):134–42.

19. Gubbels J.A., Belisle J., Onda M. et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 2006;26:5(1):50.

20. Seelenmeyer C., Wegehingel S., Lechner J. et al. The cancer antigen CA125 represents a novel counter receptor for galectin-1. J Cell Sci 2003;116:1305–18.

21. Gubbels J.A., Felder M., Horibata S. et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer 2010;20(9):11.

22. Kabawat S. E., Bast R. C., Bhan A.K. et al. Tissue distribution of a coelomicepithelium- related antigen recognized by the monoclonal antibody that recognized common surface antigens of human ovarian tumors of serous, endometrioid and clear cell types. Am J Clin Pathol 1983;79:781–5.

23. Marell A. R., Llana B. F., Alvarez A. et al. CA125 and non gynaecological benign diseases. Int. Symp. CA125: Ten years later. San-Remo, Italy. 1993. P. 1717–20.

24. Seki K., Kikuchi Y., Uesato T., Kato K. Increased serum CA125 levels during the first trimester of pregnancy. Acta Obstet Gynecol Scand 1986;65:583–6.

25. Wang M.C., Valenzuela L.A., Murphy G.P. et al. Purification of a human prostate specific antigen. Invest Urol 1979;17:159–63.

26. Ban Y., Wang M.C., Watt K.W. et al. The proteolytic activity of human prostatespecific antigen. Biochem Biophys Res Commun 1984;123:482–8.

27. Balk S.P., Ko Y.J., Bubley G.J. Biology of prostate-specific antigen. J Clin Oncol 2003;21(2):383–91.

28. Bindukumar B., Schwartz S.A., Nair M.P. et al. Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth. Neoplasia 2005;7(3):241–52.

29. Christensson A., Laurell C.B., Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:755–63.

30. Ugorski M., Laskowska A. Sialyl Lewis(a): a tumor-associated carbohydrate antigen involved in adhesion and metastatic potential of cancer cells. Acta Biochim Pol 2002;49(2):303–11.

31. Kannagi R. Carbohydrate antigen sialyl Lewis a--its pathophysiological significance and induction mechanism in cancer progression. Chang Gung Med J 2007;30(3):189– 209.

32. Kufe D.W. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene 2013;28:32(9):1073–81.

33. Koch Т., Eiffert H., Spindler M. Relevance of the new tumor marker SCC for the diagnosis and follow-up control of squamous epithelial carcinoma of the head and neck. HNO 1999;37(11):454–9.

34. Kato H. Expression and function of SCC antigen. Anticancer Res 1996;16(48): 2149–53.

35. Zhang J., Jia Q., Zou S. et al. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncol Rep 2006;15(2):455–61.

36. Парилова Н.К., Сергеева Н.С., Тюрина Н.Г. и др. Сывороточные уровни тимидинкиназы-1 (ТК-1) у больных с лимфопролиферативными заболеваниями. Онкология. Журнал им. П.А. Герцена 2012;1:33–8.

37. Eigenbrodt E., Reinacher M., Scheefers-Borchel U., Scheefers H. and Friis R. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells (review). In: Critical Reviews in Oncogenesis, CRC-Press, Boca Raton, Florida. (M. Perucho, ed.). 1992. Vol. 3 (1, 2), p. 91–115.

38. Маршутина Н.В., Сергеева Н.С. Серологические опухолевые маркеры в первичной диагностике и мониторинге больных раком молочной железы. Российский онкологический журнал 2002;4:45–8.

39. Сергеева Н.С., Русаков И.Г., Маршутина Н.В. и др. Исследование серологического опухолевого маркера Tu M2-PK у больных раком почки. Российский онкологический журнал 2005;3:30–2.

40. He Q., Zhang J., Zou S. et al. Concentration of tymidine kinase 1 (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity. Oncol Rep 2005;14:1013–9.

41. Переверзев А. С., Коган М.И. Рак простаты. Х.: Факт, 2004. 231 c.

42. Practice Guidelines and Recommendations for use of Tumor Markers in the Clinic. The National Acad Clin Biochem 2002:15:1–56.

43. Catalona W.J., Partin A.W., Slawin K.M. et al. Use of the percentage of free rostatespecific antigen to enhance differentiation of prostate cancer from benign prostatic isease: a prospective multicenter clinical trial. JAMA 1998;279:1542–7.

44. Etzioni R., Shen Y., Petteway J. C. et al. Age-specific PSA: a reassessment. Prostate 1996;7:70–7.

45. Матвеев Б.П., Бухаркин Б.В., Матвеев В.Б. Рак предстательной железы. М., 1999. C. 153.

46. Алексеев Б.Я., Нюшко К.М. Скрининг и ранняя диагностика рака предстательной железы. [Электронный ресурс]:http://uromnioi.ru/publications/30-skriningi- rannyaya-diagnostika-raka-predstatelnojzhelezy (дата обращения: 25.04.2014).

47. Lodding P., Aus G., Bergdahl S. et al. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng per mL prostate-specific antigen. I Urol 1998;159:899–903.

48. Thompson I.M, Pauler Ankerst D., Chi C. et al. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol 2007;25(21):3076–81.

49. Heidenreich A., Bolla M., Joniau S. et al. European Association of Urology. Guidelines 2010. (Пер.: О.В. Антонова, научное редактирование: Б.Я. Алексеев, К.М. Нюшко «Рекомендации по лечению рака предстательной железы» Европейской ассоциации урологов, версия 2010 г.).

50. Miller K., Abrahamsson P.А., Akakura K. et al. The Continuing Role of PSA in the Detection and Management of Prostate Cancer. Eur Urol 2007;Suppl. 6:327–33.

51. Hori S., Blanchet J.S., McLoughlin J. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer. BJU Int 2012;112:717–28.

52. Schrőder F.H., Hugosson J., Roobol M.J. et al. ERSPC Investigators. Screening and prostate – cancer mortality in a randomized. European study. N Engl J Med 2009;360:1320–8.

53. Soletormos G., Duffy M.J., Othman S. et al. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European group on tumor markers (EGTM). J Tumor Biology 2014;35(1):S1.

54. Nagele F., Petru E., Medl M. et al. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1995;86(2):259–64.

55. Корнеева И.А., Новикова Е.Г., Сергеева Н.С. Современный взгляд на маркерный рецидив рака яичников. Российский онкологический журнал 2010;2:54–7.

56. Riedinger J.M., Bonnetain F., Basuyau J.P. et al. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumor outcome. Ann Oncol 2007;18(5):881–5.

57. Ахмедова С.А. Совершенствование клинико-лабораторной концепции использования СА125 у больных раком яичников. Дис. … канд. мед. наук. М., 2003.

58. Liu P.Y., Alberts D.S., Monk B.J. et al. An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol 2007;25(24):3615–20.

59. de Bruijn H., Duk J., Vander Zee A. et al. The clinical value of SCC antigen in cancer of the uterine cervix. Tumor Biol 1998;19:505–16.

60. Ji X.Y., Pan Z.L., Shi Y.M. et al. Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients. J Cancer Res Clin Oncol 2010;136(8):1193–9.

61. Seiler T., Dohner H., Stigenbauer S. Risk stratification in chronic lymphocytic leukemia Semin. Oncol 2006;33(2):186–94.

62. Xu W., Cao X., Miao K.R. et al. Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors. Int J Hematol 2009;90(2):205–11.

63. Nisman B., Nchushtan H., Biran H. et al. Serum thymidine kinase 1 activity in prognosis and monitoring chemotherapy in lung cancer patients.Tumor Biology 2014;1:22–3.

64. Aebi S., Castiglione M. ESMO Guidelines Working Group. Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;4:21–3.

65. Guppy A.E., Rustin G.J. CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist 2002;7(5):437–43.

66. Riedinger J.M., Bonnetain F., Basuyau J.P. et al. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumor outcome. Ann Oncol 2007;18(5): 881–5.

67. Семенова А.И. Мониторинг эффективности лечения и выявление рецидивов с помощью биомаркеров. Практическая онкология 2011;12(4):171–7.

68. Uzunoglu S., Aybatlı A., Kaplan P.B. et al. Assessment of CA-125 area under the curve as a prognostic factor in patients with ovarian cancer. Med Oncol 2013;30(1):447.

69. Won E., Hurria A., Feng T. et al. Cancer and Aging Research Group. CA125 level association with chemotherapy toxicity and functional status in older women with ovarian cancer. Int J Gynecol Cancer 2013;23(6):1022–8.

70. Wechsel H.W., Petri E., Bichler K-H. et al. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Res 1999;19:2583– 90.

71. Rustin G.J., Marples M., Nelstrop A.E. et al. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001;19(20):4054–7.

72. Micke O., Prott F., Schafer U. et al. The impact of SCC antigen in the follow-up after radiotherapy in patients with cervical cancer. Anticancer Res 2000;20(6):5113–5.

73. Сергеева Н.С., Дубовецкая О.Б., Маршутина Н.В. и др. Использование серологического опухолевого маркера SСС в мониторинге больных раком шейки матки. Пособие для врачей. М., 2009.

74. Garbe C., Schadendorf D. Surveillance and follow-up examinations in cutaneous melanoma. Onkologie 2003;26(3):241–6.

75. Сергеева Н.С., Лазутина Т.Н., Мишунина М.П. и др. Определение белка S-100 как серологического опухолеа ссоциированного маркера при меланоме. Российский онкологический журнал 2008;2:19–22.

76. Сергеева Н.С., Мишунина М.П., Силина И.Г. и др. Значение уровня сывороточного белка S-100 при меланоме. Российский онкологический журнал 2007;4:13–6.

77. Сергеева Н.С., Маршутина Н.В. Опухолеассоциированные маркеры в скрининговых программах, направленных на активное выявление рака яичников: реальность, проблемы и перспективы. Практическая онкология 2010; 11(2):110–9.

78. Menon U., Gentry-Maharaj A., Hallett R. et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327–40.

79. Schrőder F.H., Hugosson J., Roobol M.J. et al. ERSPC Investigators. Screening and prostate – cancer mortality in a randomized. European study. N Engl J Med 2009;360:1320–8.

80. Fraser C.G., Matthew C.M., Mowat N.A. et al. Immunochemical testing of individuals positive for guaiac fecal occult blood test in a screening program for colorectal cancer: an bservation study. Lancet Oncol 2006;7(2):127–31.

81. NCCN [National Comprehensive Cancer Network] clinical practice guidelines in oncology. Colorectal cancer screening. Version 1. 2006.

82. Zauber A.G. Adherence to Screening in a Randomized Controlled Trial of a one Time Screening Colonoscopy versus Program of Annual Fecal Occult Blood Test (gFOBT): Implications of Lower gFOBT Adherence to Screening on Colorectal Cancer Mortality Reduction. WEO Colorectal Cancer Screening Committee Meeting. 2012.

83. Mandel J.S., Bond J.H., Church T.R. et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Eng J Med 1993;328:1365–71.

84. Collins J.F., Lieberman D.A., Durbin T.E. et al. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med 2005;142(2):81–5.

85. Sturgeon C.M., Duffy M.J., Stenman U.H. et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. Clin Chem 2008;54(12):11–79.

86. Drukier A.K., Ossetrova N., Schors E. et al. High-sensitivity blood-based detection of reast cancer by multi photon detection diagnostic proteomics. J Proteome Res 2006;5(8):1906–15.

87. Kewal K. Jain. The Handbook of Biomarkers. Jain PharmaBiotech, Basel, Switzerland. 2010. 488 p.

88. Drapkin R., von Horsten H.H., Lin Y. et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65(6):2162–69.

89. Kirchhoff C., Habben I., Ivell R. et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod 1991;45(2):350–7.

90. Bingle L., Singleton V., Bingle C.D. The putative ovarian tumor marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 2002;21:2768–73.

91. Galgano M.T., Hampton G.M., Frierson H.F. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006;19(6):847–53.

92. Moore R.G., Brown A.K., Miller M.C. et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2007;108(2):402–8.

93. Moore R.G., McMeekin D.S., Brown A.K. et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112:40–6.

94. Zhang Z., Chan D.W. The Road from Discovery to Clinical Diagnostics: Lessons Learned from the First FDA-Cleared In Vitro Diagnostic Multivariate Index Assay of Proteomic Biomarkers. Cancer Epidemiol Biomarkers Prev 2010;19(12):2995–9.

95. Fung E.T. A Recipe for Proteomics Diagnostic Test Development: The OVA1 Test, from Biomarker Discovery to FDA Clearance. Clinical Chemistry 2010;56(2):327–9.

96. Zhang Z., Bast R.C., Yu Y. et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64(16):5882–90.

97. Bast R.C. Jr, Skates S., Lokshin A., Moore R.G. Differential Diagnosis of a Pelvic Mass: Improved Algorithms and Novel Biomarkers. Int J Gynecol Cancer 2012;22 Suppl 1: S5–S8.

98. Sokoll L.J., Wang Y., Feng Z. et al. [-2] Proenzyme prostate specific antigen for prostate cancer detection: A National Cancer Institute Early Detection Research Network validation study. J Urol 2008;180:539–43.

99. Hori S., Blanchet J.S., McLoughlin J. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review ofthe emerging role of proPSAs in the detection and management of early prostate cancer. BJU Int 2012;112:717–28.

100. Mikolajczyk S.D., Millar L.S., Wang T.J. et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Can Res 2000;60:756–9.

101. Xu F.J., Yu Y-H., Li B-Y. et al. Development of two new monoclonal antibodies reactive to a surface antigen present on human ovarian epithelial cancer cells. Cancer Res 1991;51:4012–9.

102. Devine P.L., McGuckin M.A., Ward B.G. Circulating mucins as tumor markers in ovarian cancer (review). Anticancer Res 1992;12(3):709–17.

103. Xu F.J., Yu Y.H., Daly L. et al. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance rocedures. J Clin Oncol 1993;11(8):1506–10.

104. van Haaften-Day C., Shen Y., Xu F. et al. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer 2001;92(11):2837–44.

105. Xu F.J., Yu Y.H., Daly L. et al. OVX1 as a marker for early stage endometrial carcinoma.Cancer 1994;73(7):1855–8.

106. Lamour N.F., Chalfant C.E. Ceramide-1-phosphate: the "missing" link in eicosanoid biosynthesis and inflammation. Mol Interv 2005;5(6):358–67.

107. Kim C.H., Schneider G., Abdel-Latif A. et al. Ceramide-1-phosphate regulates migration of multipotent stromal cells (MSCs) and endothelial progenitor cells (EPCs) – implications for tissue regeneration. Stem Cells 2013;31(3): 500–10.

108. Ratajczak M.Z., Suszynska M., Borkowska S. et al. The role of sphingosine-1 phosphate and ceramide-1 phosphate in trafficking of normal stem cells and cancer cells. Expert Opin Ther Targets 2014;18(1):95–107.

109. Mitra P., Maceyka M., Payne S.G. et al. Ceramide kinase regulates growth and survival of A549 human lung adenocarcinoma cells. FEBS Lett 2007;581(4):735–40.

110. Liu J., Beckman B.S., Foroozesh M. A review of ceramide analogs as potential anticancer agents. Future Med Chem 2013;5(12):1405–21.

111. Dimanche-Boitrel M.T., Rebillard A. Sphingolipids and response to chemotherapy. Handb Exp Pharmacol 2013;216:73–91.

112. Bini F., Frati A., Garcia-Gil M. et al. New signalling pathway involved in the ntiproliferative action of vitamin D3 and its analogues in human neuroblastoma cells. A role for ceramide kinase. Neuropharmacology 2012;63(4):24–37.

113. Olea-Herrero N., Vara D., Malagarie-Cazenave S. et al. The cannabinoid R+ methanandamide induces IL-6 secretion by prostate cancer PC3 cells. J Immunotoxicol 2009;6(4):249–56.

114. Date T., Mitsutake S., Igarashi Y. Ceramide kinase expression is altered during macrophage-like cell differentiation of the leukemia cell line HL-60. In Vitro Cell Dev Biol Anim 2007;43(10):321–3.

115. Ruckhäberle E., Karn T., Rody A. et al. Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer. J Cancer Res Clin Oncol 2009;135(8):1005–13.